{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adverse+Skin+Reaction",
    "query": {
      "condition": "Adverse Skin Reaction"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T05:32:36.673Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04723602",
      "title": "Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ebola Virus Disease",
        "Marburg Virus Disease"
      ],
      "interventions": [
        {
          "name": "cAd3-Marburg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cAd3-EBO-S",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Albert B. Sabin Vaccine Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 32,
      "start_date": "2021-01-06",
      "completion_date": "2021-12-14",
      "has_results": false,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-07-23T05:32:36.673Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04723602"
    },
    {
      "nct_id": "NCT06011629",
      "title": "Aquacel Hypersensitivity Dressing in TJAs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Contact Allergic Dermatitis",
        "Adverse Skin Reaction"
      ],
      "interventions": [
        {
          "name": "Aquacel dressing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 396,
      "start_date": "2023-08-18",
      "completion_date": "2025-06-03",
      "has_results": false,
      "last_update_posted_date": "2025-06-26",
      "last_synced_at": "2026-07-23T05:32:36.673Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06011629"
    },
    {
      "nct_id": "NCT03576469",
      "title": "A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "CVI - Common Variable Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "C1-esterase inhibitor [recombinant] (C1-INH-R)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "IMMUNOe Research Centers",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-06-13",
      "completion_date": "2020-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-02-15",
      "last_synced_at": "2026-07-23T05:32:36.673Z",
      "location_count": 1,
      "location_summary": "Centennial, Colorado",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03576469"
    },
    {
      "nct_id": "NCT06406114",
      "title": "Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Drug Allergy",
        "Cephalosporin Allergy",
        "Drug Hypersensitivity",
        "Antibiotic Allergy",
        "Beta Lactam Adverse Reaction",
        "Drug-Induced Anaphylaxis",
        "Cephalosporin Reaction"
      ],
      "interventions": [
        {
          "name": "Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing",
          "type": "DRUG"
        },
        {
          "name": "Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge",
          "type": "DRUG"
        },
        {
          "name": "Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge",
          "type": "DRUG"
        },
        {
          "name": "Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin double-blind placebo-controlled drug challenge",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 300,
      "start_date": "2025-05-05",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-07-23T05:32:36.673Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06406114"
    },
    {
      "nct_id": "NCT03505164",
      "title": "The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Doxorubicin Adverse Reaction",
        "Cardiomyopathies, Secondary",
        "Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 64 Years · Female only"
      },
      "enrollment_count": 42,
      "start_date": "2017-01-17",
      "completion_date": "2020-07-06",
      "has_results": false,
      "last_update_posted_date": "2021-04-27",
      "last_synced_at": "2026-07-23T05:32:36.673Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Oak Park, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Oak Park",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03505164"
    },
    {
      "nct_id": "NCT02987257",
      "title": "NATIENS: Optimal Management and Mechanisms of SJS/TEN",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stevens-Johnson Syndrome",
        "Toxic Epidermal Necrolyses"
      ],
      "interventions": [
        {
          "name": "Harmonized supportive care",
          "type": "DRUG"
        },
        {
          "name": "Etanercept 50 mg sc day 1 and day 4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2023-03-21",
      "completion_date": "2025-10-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-07-23T05:32:36.673Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02987257"
    },
    {
      "nct_id": "NCT04340388",
      "title": "Contribution of Dolutegravir to Obesity and Cardiovascular Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV-1-infection",
        "Antiviral Drug Adverse Reaction",
        "Vascular Diseases",
        "Cardiovascular Abnormalities",
        "Abnormality of Adipose Tissue",
        "Body Weight Changes",
        "Body Fat Disorder",
        "HIV-Associated Lipodystrophy Syndrome"
      ],
      "interventions": [
        {
          "name": "Dolutegravir 50 MG",
          "type": "DRUG"
        },
        {
          "name": "Antiretroviral/Anti HIV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 10,
      "start_date": "2020-09-17",
      "completion_date": "2023-02-25",
      "has_results": false,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-07-23T05:32:36.673Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04340388"
    }
  ]
}